The Westmead Institute for Medical Research Constitution is available here.


The Board of The Westmead Institute for Medical Research is comprised of 11 directors, led by Chair, Mr Philip Chronican. It includes appointees of the University of Sydney, the NSW Government, the Westmead Institute for Medical Research Foundation and the Westmead Hospital Foundation.

The Board is responsible for oversight of the policies, strategic direction and management of the Institute.


Philip Chronican (Chair)

Philip is an independent director of the Westmead Institute Board of Directors.

He is a non-executive director of the National Australia Bank, the Bank of New Zealand and Chairman of the NSW Treasury Corporation.  He is also a director of both the Banking and Finance Oath and the Juvenile Diabetes Research Foundation.

In his executive career he held senior executive roles in the banking industry across Australia and New Zealand in a career that spanned over 35 years. Roles included CEO Australia for ANZ and Group Executive Institutional Banking and Chief Financial Officer for Westpac Banking Corporation..

Phil O'Connell

Phil is an executive director of the Board.

Experience and expertise

Professor Phil O'Connell is Executive Director of WIMR and Director of the Centre for Transplant and Renal Research.

Philip undertook a PhD in endothelial cell adhesion molecules at the University of Melbourne and had further training in transplant immunology as a postdoctoral research fellow with Professor Terry Strom, Harvard Medical School. His major research interests are in the development of islet transplantation as a main stream treatment for type 1 diabetes and the use of genomics as a marker of renal allograft dysfunction.  He was a principle investigator of the NIH funded GOCAR study. He is director of the Australian Clinical Islet Transplant Consortium, which has undertaken Australia’s first multicentre clinical trial of islet transplantation. 

Read more

Bill Ketelbey

Dr Bill Ketelbey is a non-executive director.

Experience and expertise 

Dr Bill Ketelbey is a highly experienced healthcare, pharmaceutical and biotech sector professional, with more than 30 years’ experience, including most recently as CEO and Managing Director for the ASX listed biotechnology company, Actinogen Medical (ASX:ACW). Actinogen Medical is developing innovative treatments for Alzheimer’s disease and the cognitive impairment associated with neurogenerative and metabolic diseases. Prior to joining Actinogen Medical, Dr Ketelbey was an independent consultant, focusing on the Healthcare and Pharmaceutical industries in the APAC region and held a number of senior positions at Pfizer, including Regional Vice-President of Medical Affairs at Pfizer for Australia/New Zealand, Japan, Canada and Korea, Senior Vice-President/Senior Medical Director for Pfizer Japan and Country Medical Director for Pfizer ANZ.

Dr Ketelbey has a solid track record of product development over his years in the industry leading to the successful registration and commercialisation of numerous market leading medicines across a broad range of therapeutic areas.


Dr Ketelbey is a medical graduate from the University of the Witwatersrand, South Africa, a Fellow of the Faculty of Pharmaceutical Physicians from the Royal College of Physicians in the UK, has an MBA from Macquarie Graduate School of Management, Australia and is a Graduate of the Australian Institute of Company Directors

Michael Rose AM

Michael is the Chair of the Committee for Sydney, an urban policy think tank that advocates better policy outcomes for Sydney. He is also Chairman of Northwest Rapid Transit (NRT Group) and sits on the board of the Sydney Harbour Federation Trust.  He is a lawyer by background and the former Chief Executive Partner of one of Australia’s leading law firms.

Michael has served on the boards of a number of Government, arts and not-for-profit organisations.  He has a senior advisory role at UNSW and is a Fellow of the Australian Institute of Company Directors.

Julia Strelitz

Julia is a Non-Executive Director.

Julia is a Partner at PricewaterhouseCoopers whose experience is in providing financial services within the healthcare sector. She has worked with both public and private sector healthcare providers across Federal, State and hospitals effecting financial and operational improvements, providing financial analysis, productivity reviews and program evaluations.


Bachelor of Commerce, University of Witwatersrand, South Africa

Bachelor of Accounting, University of Witwatersrand, South Africa

Member of the Institute of Chartered Accounts in Australia (ICAA).

Special responsibilities

Julia is Chair of the Audit and Risk Committee.

Robyn Ward AM

Professor Robyn Ward AM FAHM represents the University of Sydney on the Board.

Professor Robyn Ward AM FAHM joined the University of Sydney in July 2018 as the inaugural Executive Dean of the Faculty of Medicine and Health. She was the former Deputy Vice-Chancellor (Research) and Executive Dean (Acting) of the Faculty of Medicine of the University of Queensland.
Professor Ward is an academic leader, cancer researcher and medical oncologist. She chairs the Commonwealth Medical Services Advisory Committee (MSAC), and serves on the Council and Executive of the Australian Academy of Health and Medical Sciences. In 2013 she was made Member of the Order of Australia (AM) for significant service to medical research and patient care in the field of oncology.

Graeme Loy

Mr Graeme Loy represents the Western Sydney Local Health District (WSLHD).

Over the last 12 years Graeme has held a number of executive roles, including Chief Executive for NSLHD. His knowledge of both clinical and corporate services includes a strong focus on system performance through healthy relationships.
Graeme has accumulated significant experience in all aspects of leadership in both the public and private sectors. He takes great pride being able to deliver highly complex clinical services through high performing teams.
His breadth of knowledge spans facility, district and statewide environments and enables him to couple strategic direction with the broader improvement and research goals, including ensuring optimal provision of safe, high quality and timely clinical services in concert with the needs of the community and the health system.
With patients as his principle focus Graeme strives to support NSW Health to deliver high quality care and brings a simple motto to each discussion – “What if it was your mum?”

Ivan Power

Mr Ivan Power represents The Westead Institute for Medical Research Foundation (WIMR Foundation). 

Ivan has extensive experience in financial markets and investment management.  He has spent over twenty years at Macquarie Group in a variety of senior roles in Sydney and London, currently leading Portfolio & Performance for Macquarie Group.  He previously worked at KPMG in Sydney.

Ivan is actively involved in various community initiatives, being Chair of Opportunity Child, a Director of the Westmead Institute for Medical Research (WIMR) and Chair of the WIMR Foundation.  He was the founding Chair of Businesses for Islington Giving (BIG) during his time in London.

Ivan is a qualified Chartered Accountant (Australia), holds a Masters in Applied Finance from Macquarie University and Bachelor of Accounting from the University of Technology, Sydney, is a Sloan Fellow from London Business School and a certified organisational coach through IECL Sydney.  He lives in Sydney with his partner and four children.

John Dakin

Mr John Dakin represents the Westmead Hospital Foundation.

John Dakin is a financial, administrative and operations professional with over 30 years experience in senior management roles generally in large complex organisations. His main emphasis throughout his career has been to ensure delivery of efficient, cost effective systems to support and enhance the overall business operation.
John was responsible for a number of major projects including project directing construction of two major research buildings, a large scale animal research facility, leading the sale of a merchant bank to Macquarie Bank, purchasing two major private hospital groups and the relocation of a major medical research institute into Garvan.

Professor Barbara Messerle

Professor Barbara Messerle is Provost and Deputy-Vice Chancellor at the University of Sydney

Professor Messerle studied Science at the University of Sydney, with a PhD in method development for molecular structure determination. Following a postdoctoral position at the ETH, Zurich, where she worked on the three dimensional structures of proteins with Nobel Laureate Professor Kurt Wuethrich, Prof Messerle returned to Australia and after a number of years as an ARC Queen Elizabeth II Fellow and ARC Senior Research Fellow, became an academic and Head of the Chemistry School at the University of New South Wales. Professor Messerle was previously the Executive Dean, Faculty of Science and Engineering, Macquarie University 2015-2019.
Professor Messerle’s research today is about developing organometallic catalysts and new methodologies for promoting the selective and efficient synthesis of important biologically active molecules. Understanding the structure and function of reactive molecular species has always underpinned her research. Professor Messerle has authored over 115 peer reviewed research publications, been awarded more than $17m in grant funding, and has supervised or co-supervised 19 PhD students and 2 Masters students to completion.
Prof Messerle’s professional affiliations include Fellow of the Royal Australian Chemical Institute (FRACI); Graduate of the Australia Institute of company Directors (GAICD); and Fellow of the Royal Society of NSW (FRSNSW). Member of the Australian and New Zealand Society for Magnetic Resonance (ANZMAG); Member of the American Chemical Institute.